Advertisement

Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Financing › Details

Carelane–SEVERAL: investment, 202406 pre-seed financing round €800k led by HTGF

 

Period Period 2024-06-20
Organisations Money taker Carelane GmbH
  Money source SEVERAL
Products Product clinical research software
  Product 2 venture capital
Person Person Baltrukovich, Natalya (High-Tech Gründerfonds 202406 Investment Manager)
     

High-Tech Gründerfonds Management GmbH. (6/20/24). "Press Release: Health Tech Start-up Carelane Raises €800,000 in Pre-Seed Funding to Revolutionize Clinical Trial Software".

> Carelane Secures €800,000: Carelane has successfully closed its pre-seed funding round, gathering €800,000, led by High-Tech Gründerfonds to expand its novel clinical trial software across Europe and the US.

> Innovative Unified Platform: Addressing the inefficiencies in clinical trials, Carelane’s platform integrates multiple necessary functions into one system, digitizing study protocols and processes to reduce complexity and avoid costly amendments.

> Proven Impact: Carelane demonstrated its platform’s effectiveness by reducing the trial management workload for its initial customer by more than 80% through enhanced collaboration features and process automation.


Carelane, a life sciences technology start-up, has announced the successful closure of its pre-seed funding round, raising €800,000. The investment, led by High-Tech Gründerfonds (HTGF), will fuel the expansion of its unified platform designed to streamline clinical trials, significantly reducing the operational burdens faced by pharmaceutical companies, contract research organizations, and academic researchers.

Clinical trials today face inefficiencies and high costs because they are reliant on multiple disjointed software systems for essential tasks such as data management, eConsent, tokenization, sample tracking, drug supply, and patient follow-up. The time required for integration and the challenges of process orchestration, along with regulatory compliance demands for unified audit trails, further complicate the situation.

Carelane uniquely integrates these features into a single platform, significantly reducing the complexity and expense associated with traditional clinical trial management. With Carelane, study protocols are structured, digitized documents rather than text-based, enabling seamless integration and continuous alignment of study design, conduct, and analysis. This approach avoids costly amendments that can cost millions of dollars.

The platform not only enhances security using the latest cloud technologies but also includes features for managing common trial processes such as sample shipments, site onboarding, and patient consents. All of this is achieved while maintaining a unified audit trail.

With this new capital, Carelane will broaden its reach across Europe and the United States. The start-up already demonstrated substantial traction before this funding round by reducing trial management burden by more than 80% for its initial customer through enhanced collaboration features and process automation. Looking ahead, Carelane plans to expand its platform with source data capture capabilities, including automatic data ingestion from electronic health records (EHRs) and AI features, setting the stage for a forthcoming seed funding round.

Carelane offers a one-stop-shop platform focused on real world evidence research, addressing costly and inefficient clinical trials caused by fragmented software and a lack of integration between healthcare and clinical research systems. By unifying the entire clinical trial process in one platform, Carelane provides a strong value-proposition with benefits for both patients and research stakeholders.
Dr. Natalya Baltrukovich, Investment Manager at HTGF

The study setup was highly intuitive and the time we saved on site selection and onboarding was impressive. By adapting the Carelane workflow templates and adding them to our study setup, we only needed to send out one email; everything else was automated. Our team quickly grasped how to build our case report form, which included complex fields with conditions and calculations. What really made a difference to me was the ability to invite collaborators and reviewers, it allowed them to comment on each individual item and accelerated the study setup tremendously.
Prof. Dr. Martin Hoenigl, President of European Confederation of Medical Mycology (ECMM), Medical University of Graz

The system was very easy to use. Even without training, we could follow all the processes and complete tasks with ease.
Prof. Dr. Emmanuel Roilides, Hippokration General Hospital


About Carelane

Carelane is a health tech start-up focused on addressing the inefficiencies in clinical trials by integrating multiple essential functions into a single, streamlined system, thereby digitizing study protocols and processes. After launching in 2023, it quickly gained traction and closed its first funding round successfully in the beginning of 2024. Both founders have extensive experience working in health tech, having worked with the German government, private enterprises, and renowned research hospitals. They are driven by the vision to empower researchers and healthcare professionals, ultimately saving time that can be redirected towards groundbreaking research and innovations. Carelane stands at the forefront of transforming the clinical trial process, making it intuitive, efficient, and seamlessly integrated.


Media Contact

Carelane GmbH
Yannick Boerner, CEO & CTO
office@carelane.io


About High-Tech Gründerfonds

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 750 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 6 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 180 companies.

Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
www.htgf.de/en


Media contact

High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
t.jacob@htgf.de

Dr. Natalya Baltrukovich – Investment Manager

   
Record changed: 2024-06-20

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x200px

More documents for Carelane GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top